Medical society guidelines in cardio-oncology

Cardio-oncology is a growing field at the intersection of cardiovascular health and oncological care, responding to the escalating incidence of cardiovascular complications associated with cancer therapies. This chapter explores current applications and practices in cardio-oncology, emphasizing evidence-based tools and guidelines crucial for mitigating treatment-related cardiovascular risks. Central to these efforts are published guidelines and other risk assessment tools that have been developed by medical societies or for use with medical society guidelines. These guidelines enable precise risk assessments for oncology patients prior to, during, or after initiating therapies known to induce cardiotoxicity, facilitating preventive strategies. Furthermore, the integration of baseline cardiovascular assessments into oncological practice supports comprehensive management of preexisting cardiovascular disease and risk factors, thereby optimizing treatment outcomes. This chapter underscores the critical role of multidisciplinary collaboration among cardiology, oncology, and hematology societies. Future directions focus on enhancing predictive biomarkers, refining risk assessment tools, and establishing dedicated cardio-oncology services to meet the evolving clinical demands and improve patient prognosis in the field of cardio-oncology.